Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

- Favorable results for secondary endpoints support outcomes benefit

HAYWARD, Calif., May 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C). All patients in the FRANCIS trial received once daily doses of 80mg of Lipitor (atorvastatin calcium), plus 500mg of varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles.

The pre-specified primary endpoint analysis was conducted when 500 patients reached at least eight weeks of treatment after an ACS event. In addition to meeting the primary endpoint, additional efficacy analyses at a variety of time points showed positive results for all clinically important secondary endpoints. The initial data review demonstrated:

- A statistically significant reduction in LDL-C at all prospectively defined time points and statistically significant reductions in total cholesterol and non-HDL cholesterol

- Varespladib's immediate and selective inhibition of sPLA2 effectively suppressed inflammation following the index event and was further evidenced by a statistically significant reduction in C-reactive protein.

- A statistically significant greater proportion of patients treated with varespladib achieved LDL-C levels of 70mg/dL or less (a target established by the American Treatment Program III for high-r
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/24/2013)... May 24 (HealthDay News) -- Patients hospitalized for heart ... they,re admitted on Mondays or in the morning, a ... stay are highest among heart failure patients admitted in ... who are scheduled to present their findings Saturday in ... Association of the European Society of Cardiology. ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... used to treat glaucoma may cause droopy eyelids and ... to a new study. The drugs, known as ... pressure, have already been shown to cause blurred vision, ... suggesting that the new findings could lead to labeling ... when prescribing these drugs, the researchers added, particularly as ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV ... consumers compare the features and services offered by ... released the rankings of the best rural ... viewing on their website. , BestSatelliteProviders.com ... Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers ...
Breaking Medicine News(10 mins):Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... ,A new study shows that poor lung function during ... including birth weight, height, and gender. Researchers from Newcastle University ... all aged 14 years. Follow-up data also were obtained for ... showed that several factors were related to poorer lung function ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... 2010 Knee osteoarthritis (OA) accounts for more disability in ... proven cardiovascular and other health benefits, can increase stresses on ... the December 2009 issue of PM&R: The journal of ... knee, hip and ankle joint motions of running barefoot versus ...
... Extremity War Injuries Symposium was held in Washington, D.C., ... surgeons, researchers, experts from governmental agencies, and others to ... Iraq and Afghanistan and to discuss ways to synergize ... summarizing the findings from the symposium is published in ...
... pinpointed the prime factors identifying which elderly persons are ... The researchers, led by Jeffrey M. Lyness, M.D., professor ... in an article in the December issue of The ... for people in the high-risk group hold promise for ...
... , SCOTTSDALE, Ariz., Dec. 31 ... real estate investment trust, announced the completed acquisition of ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... is 100% leased to community hospitals that are wholly-owned ...
Cached Medicine News:Health News:News briefs from the January issue of Chest 2Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Running shoes may cause damage to knees, hips and ankles 2Health News:Extremity war injuries: More research is needed 2Health News:Extremity war injuries: More research is needed 3Health News:Study identifies those elderly most at risk for major depression 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 3
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
Medicine Products: